Public Providers and Procurement Minister Anita Anand stated right this moment that Canada is able to deploy a brand new COVID vaccine from Johnson & Johnson’s pharmaceutical division, Janssen, as soon as it receives regulatory approval from Well being Canada — however she could not say what number of pictures will probably be obtainable within the coming weeks.
The U.S. Meals and Drug Administration’s vaccines and associated organic merchandise advisory committee will meet Friday to evaluate the scientific trial knowledge for this vaccine. A closing U.S. determination on issuing emergency use authorization (EUA) may comply with as early as this weekend.
The identical FDA committee met in early December to evaluate Pfizer’s vaccine and, a day later, the EUA was issued. Later that month, the FDA committee met to evaluate the Moderna vaccine and an EUA was granted the following day.
Well being Canada may make the identical determination in a matter of days. The U.S. and Canada have been in synch on previous COVID-19 vaccine approvals.
A spokesperson for the division stated Well being Canada “intends to be as aligned as potential with the selections of our key regulatory companions, as soon as the entire knowledge required to decide has been acquired and reviewed.”
“Well being Canada continues to obtain knowledge from Janssen,” the spokesperson instructed CBC Information.
WATCH: Anand offers an replace on Johnson & Johnson’s COVID-19 vaccine
The CBC’s Tom Parry asks Procurement Minister Anita Anand what number of doses of Johnson & Johnson’s COVID-19 vaccine Canada will obtain after it is authorized by Well being Canada. 4:56
Canada has ordered 10 million doses from Johnson & Johnson with choices for as much as 28 million extra, if obligatory. Most of these pictures are anticipated to reach by the top of September.
Anand stated she had a dialog with executives from Johnson & Johnson final week “to make sure we’re heading in the right direction by way of these deliveries and to press them on when exactly these deliveries could be arriving in Canada.”
Drug makers ‘reluctant’ to set deadlines with out approvals: Anand
Requested if she is aware of what number of doses will probably be delivered within the second quarter of this yr — when Canada’s vaccination marketing campaign is anticipated to ramp up — Anand stated “that could be a negotiation that we’re at the moment engaged in and I’ll present data referring to the main points of these deliveries as quickly as I’ve them.”
Anand stated it is “too early” to say what number of doses, if any, Canada will obtain within the April by means of June interval.
She stated vaccine producers are “reluctant” to offer agency supply dates with a regulatory evaluate course of nonetheless pending, however she has assured Johnson & Johnson that “ Canada is prepared for the deployment and distribution of vaccines” and that these pictures will probably be put to make use of straight away.
Final month, the corporate confirmed with U.S. officers that it was on observe to ship 100 million doses to the American market by the top of June.
The corporate has signed offers to produce pictures at vegetation in Indiana, Maryland and Michigan within the U.S. and different services in Europe with the intention to meet its contractual obligations.
“We’re very assured and on observe to fulfill all of our commitments,” the corporate’s CFO, Joseph Wolk, instructed CNBC in January.
The corporate’s Canadian division has not but provided comparable assurances.
“It’s untimely to deal with the provision specifics of our vaccine candidate,” a spokesperson for the corporate stated in an electronic mail to CBC Information.
“Janssen is constant to work with Well being Canada to finish the rolling submission course of,” the spokesperson stated.
The Johnson & Johnson product, which requires just one shot as a substitute of two just like the Moderna and Pfizer vaccines, could be a lot simpler for public well being officers to manage because it stays steady in a typical fridge for months.
Not like these two pictures, that are based mostly on mRNA technlogy, the Johnson & Johnson product makes use of a extra typical viral vector load vaccine know-how. Thousands and thousands of individuals may develop some type of antibody safety in opposition to COVID-19 with only a single dose.
In U.S. scientific trials, the product was discovered to be 72 per cent efficient in stopping moderate-to-severe instances of COVID-19.
Importantly, the product additionally demonstrated full safety in opposition to COVID-19-related hospitalization and loss of life, 28 days post-vaccination.
The corporate has stated the single-shot vaccine has “the potential to considerably cut back the burden of extreme illness.”